Fresenius Medical Care Fresenius Kabi Fresenius Helios Fresenius Vamed
in new markets - Fresenius Medical Care
for further growth - Fresenius Kabi
for better health - Fresenius Helios
for greater efficiency - Fresenius Vamed
close

Seizing opportunities > in new markets

Asia is an important growth market for Fresenius Medical Care. Approximately 620,000 patients with chronic kidney failure are currently being treated in this region, and every year this number increases by about 10 to 11%. We will continue to take advantage of this growth potential. The significant demand for dialysis services offers substantial opportunities to expand our network of clinics in the Asian countries.

In 2008, Fresenius Medical Care achieved sales of US$ 606 million in the Asia-Pacific region. Our goal is to continue our strong organic growth and to increase sales to more than US$ 800 million in constant currency by 2010.

FRESENIUS MEDICAL CARE IN ASIA
  2008 2007 Change
Sales (in million US$) 606 541 12%
Employees (December 31) 3,558 3,095 15%
Dialysis patients (December 31) 9,158 7,789 18%
Dialysis treatments (million) 1.34 1.21 11%
Dialysis clinics (December 31) 125 105 19%
 

READ MORE ABOUT FRESENIUS MEDICAL CARE >>

close
in new markets - Fresenius Medical Care
close

Seizing opportunities > for further growth

With the acquisition of APP Pharmaceuticals, Fresenius Kabi has achieved a leading position in the global market for intravenously administered generic drugs. APP Pharmaceuticals has a strong drug registration portfolio pending and over 70 products under development, opening up new growth opportunities.

At the same time, we are seizing the opportunity of introducing selected Kabi products into the US, with initial focus on parenteral nutrition. We are also planning to launch selected APP IV drugs outside the US.

APP PHARMACEUTICALS IN FIGURES
  2008
Sales US$ 777 million
EBITDA, adjusted* US$ 317 million
EBITDA margin, adjusted* 40.8%
Employees (December 31, full-time equivalent) 1,487
Production facilities 3
Produkte >100
Number of products ~17%
 

READ MORE ABOUT FRESENIUS KABI >>

close
for further growth - Fresenius Kabi
close

Seizing opportunities > for better health

At Fresenius Helios, our commitment is to provide the highest medical quality and care. We aim to offer advanced and proven best-in-class diagnosis and treatment methods for the benefit of our patients. We continuously invest in high-quality, state-of-the-art medicine, and aim to measure and improve the quality of medical care.

Our target ist that our quality indicators should be better than the German average. With a mortality rate of SMR < 1, this was accomplished, among others, for major illnesses shown below.

HELIOS QUALITY INDICATORS
Indications/
standardized mortality rate (SMR)*
2008
SMR
2007
SMR
Acute myocardial infarction 0.73 0.79
Heart failure 0.73 0.85
Stroke 0.83 1.01
Acute cerebral infarction 0.81 0.99
Pneumonia 0.71 0.85
 

READ MORE ABOUT FRESENIUS HELIOS >> 

close
for better health - Fresenius Helios
close

Seizing opportunities > for greater efficiency

Fresenius Vamed is a leading international provider of services in the planning, construction, and management of health care facilities. Our complete value chain and our more than 25 years of international experience are key to providing effective support for hospitals at every stage of their life cycle, and thus contributing towards their successful operating performance. For us, each project is another opportunity to prove our competence.

Hospitals face the dual challenge of increasing efficiency and reducing expenditure. We support hospitals by offering comprehensive process know-how and by taking over medical-technical services and management functions.

VAMED SERVICES
   
Service contracts* for   140 clinics
  ~ 50,000 beds
among others:  
Vienna General Hospital and University Clinics (AKH) ~ 2,100 beds
Charité Hospital Berlin ~ 3,200 beds
University Clinic Hamburg-Eppendorf ~1,370 beds
Prince Court Medical Center, Kuala Lumpur ~ 330 beds
Al Ain Hospital, Abu Dhabi ~ 450 beds
 

READ MORE ABOUT FRESENIUS VAMED >>

close
for greater efficiency - Fresenius Vamed
  • Print page
  • Save as PDF
  • Add to Cart
  • Recommend Page

Print

DIVIDEND

Based on the Group’s excellent financial results, we are pleased to increase the dividend for 2008. We are therefore continuing our earnings-linked dividend policy. For the 16th consecutive year we are proposing to our shareholders a dividend increase to € 0.70 (2007: € 0.66) per ordinary share and € 0.71 (2007: € 0.67) per preference share – an increase of 6% per share. The total proposed dividend distribution will be € 113.6 million, equivalent to 25% of adjusted Group net income (before special items).

We have added a total return calculator as a service on our website at www.fresenius.de/Investor Relations/Shares/Share Price. You can use the calculator to determine the total return on your Fresenius shares including dividend payments.

SHAREHOLDER STRUCTURE

The Else Kröner-Fresenius Foundation is the largest shareholder of Fresenius SE, holding approximately 58% of the voting shares. Allianz Lebensversicherungs-AG claims to hold between 5 and 10% of the voting shares. In addition, we have received notifications pursuant to the German Securities Trading Act (Wertpapierhandelsgesetz) from Fidelity (Great Britain: over 5%; United States: over 3%).For further details, please see pages 159 and 160 of the Notes.

At the beginning of 2009, a shareholder survey covering 90% of our subscribed capital identified the ownership of 98% of the ordinary shares and 82% of the preference shares.

According to this survey, a total of 289 institutional investors held about 86.8 million shares (54% of subscribed capital). This was split into 24.0 million ordinary shares (30% of the ordinary shares) and 62.8 million preference shares (78% of the preference shares). 2.0 million ordinary shares and 3.5 million preference shares were identified as retail holdings.

The top ten investors hold approximately 16% of the ordinary share capital and approximately 27% of the preference share capital. Both share classes are mostly held by investors in Germany and Great Britain. 

Shareholder Structure Ordinary Shares

Shareholder Structure Preference Shares

EARNINGS PER SHARE

Adjusted for special items relating to the acquisition of APP Pharmaceuticals, the Fresenius Group achieved adjusted earnings per ordinary share of € 2.85 and adjusted earnings per preference share of € 2.86 in 2008 (2007: € 2.64 per ordinary share; € 2.65 per preference share). This is an increase of 8% for both share classes (11% in constant currency). Further details on earnings and information on adjusted earings per share can be found on page 74 of the Management Report and on page 137 of the notes

KEY DATA OF THE FRESENIUS SHARES
  2008 2007 2006 2005 2004
Number of shares 161,143,734 155,164,770 51,451,292 50,722,280 40,971,038
   Ordinary
   shares
80,571,867 77,582,385 25,725,646 25,361,140 20,485,519
   Preference
   shares
80,571,867 77,582,385 25,725,646 25,361,140 20,485,519
           
Stock exchange quotation ordinary share1) (€)          
   High 60.87 63.35 51.326) 36.386) 27.836)
   Low 31.93 50.17 35.476) 25.196) 20.106)
   Year-end
   quotation  
36.23 56.00 50.576) 35.336) 24.886)
Stock exchange quotation preference share1) (€)          
   High
59.25 63.12 55.326) 39.836) 24.096)
   Low 37.23 50.70 37.416) 22.976) 16.966)
   Year-end
   quotation
41.59 56.90 54.276) 38.226) 22.946)
           
Market capitalization2) (million €) 6,270 8,759 8,091 5,596 2,939
           
Beta factor3) 0.85 0.80 0.88 0.74 0.33
           
Total dividend distribution (million €) 113.64) 103.2 88.8 75.8 55.9
           
Per share in €          
Dividend ordinary share 0.704) 0.66 0.57 0.496) 0.456)
Dividend preference share
0.714) 0.67  0.58  0.506)  0.466)
Earnings per ordinary share 2.855) 2.64 2.156) 1.766) 1.366)
Earnings per preference share 2.865) 2.65 2.166) 1.776) 1.376)